title: New medical therapies of acromegaly.
abstract: Acromegaly is a rare disease associated with significant morbidity and increased mortality. Treatment of acromegaly aims at controlling growth hormone hypersecretion, improving patients' symptoms and comorbidities and normalizing mortality. The therapeutic options for acromegaly include surgery, medical therapies and radiotherapy. However, despite all these treatment options, approximately one-half of patients are not adequately controlled. Progress in molecular research has made possible to develop new therapeutic strategies to improve control of acromegaly. This article will review the new medical approaches to acromegaly which consist in evolution of traditional therapeutic protocols and development of new molecules with different profiles of activity.
authors.affiliation: Endocrinology, University of Brescia, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Maffezzoni
authors.affiliation: Endocrinology, University of Brescia, Italy.
authors.forename: S
authors.initials: S
authors.lastname: Frara
authors.affiliation: Endocrinology, University of Brescia, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Doga
authors.affiliation: Endocrinology, University of Brescia, Italy; Endocrinology, ASST Carlo Poma of Mantua, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Mazziotti
authors.affiliation: Endocrinology, University of Brescia, Italy. Electronic address: a.giustina@libero.it.
authors.forename: A
authors.initials: A
authors.lastname: Giustina
mesh_terms: D000172:Acromegaly / Q000188:drug therapy*; D000236:Adenoma / Q000188:drug therapy*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001905:Botulinum Toxins / Q000627:therapeutic use; D000077465:Cabergoline; D017024:Chemotherapy, Adjuvant; D018491:Dopamine Agonists / Q000627:therapeutic use*; D004873:Ergolines / Q000627:therapeutic use; D049912:Growth Hormone-Secreting Pituitary Adenoma / Q000188:drug therapy*; D019382:Human Growth Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D018931:Antineoplastic Agents, Hormonal; D018491:Dopamine Agonists; D004873:Ergolines; D011993:Recombinant Fusion Proteins; C585484:SXN101959; D019382:Human Growth Hormone; D013004:Somatostatin; C517782:pasireotide; D001905:Botulinum Toxins; D000077465:Cabergoline; C406545:pegvisomant; D015282:Octreotide
keywords: Acromegaly; Antisense molecules; Botulin neurotoxin; Oral octreotide; Pasireotide; Somatostatin analogs